FL 115
Alternative Names: FL-115Latest Information Update: 10 Aug 2026
At a glance
- Originator Suzhou Forlong Biotechnology
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Bladder cancer; Solid tumours
Most Recent Events
- 04 Aug 2026 Forlong Biotechnology plans a phase III trial for Bladder cancer in 2027 (IV)
- 29 May 2026 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 17 Apr 2026 Pharmacokinetics data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)